Track topics on Twitter Track topics that are important to you
EQS Group-News: Zur Rose Group AG
/ Key word(s): Development of Sales
Zur Rose Group posts acceleration of growth in third quarter 2019
- Revenue up 30 per cent in the first nine months of 2019
- Strategic cooperation with the German Association of General Practitioners on
- Group Management expanded: Betül Susamis Unaran becomes Chief Strategy and
The Zur Rose Group remains on the growth track: including the sales of medpex, Europe's largest e-commerce pharmacy generated revenue of CHF 1,157.8 million in the first nine months of 2019. This represents a rise of 30.2 per cent (32.4 per cent in local currency terms) compared with the same period last year and a further acceleration of growth compared to the first half of the year. Excluding medpex, sales rose by 12.5 per cent (14.7 per cent in local currency terms). In Germany, revenue including medpex rose by 50.2 per cent in local currency terms, with the Swiss business up by 5.0 per cent.
e-prescriptions: cooperation with the German Association of General Practitioners
Partnership with health insurers
Group Management strengthened
1) PromoFarma consolidated per 14 September 2018
Key revenue figures
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, payers and industry.
The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,300 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com
 As the separation of the mail-order business has not yet been completed, no medpex revenues have been consolidated in the first nine months of 2019.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||894423|
|End of News||EQS Group News Service|
Original Article: Zur Rose Group posts acceleration of growth in third quarter 2019NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...